We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tarsus Pharmaceuticals Inc | NASDAQ:TARS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.18 | 0.49% | 37.03 | 34.71 | 37.00 | 37.85 | 36.35 | 37.00 | 679,559 | 01:00:00 |
Presentation DetailsDate: Wednesday, July 14Time: 1:30 PM ET/10:30 AM PTWebcast: https://wsw.com/webcast/ladenburg7/tars/2438302
The live webcast will be hosted on ir.tarsusrx.com and available for replay for a period of 90 days.
About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.
Media Contact: | |
SuJin Oh | |
Shop PR | |
(917) 841-5213 | |
sujin@shop-pr.com | |
Investor Contact: | |
Patti Bank | |
Westwicke Partners, an ICR company | |
(415) 513-1284 | |
IR@tarsusrx.com |
1 Year Tarsus Pharmaceuticals Chart |
1 Month Tarsus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions